Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c‑met

Shu,Yan; Xie,Bo; Liang,Zhen; Chen,Jing

doi:10.3892/ol.2017.7561

Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c‑met

Authors:
- Yan Shu
- Bo Xie
- Zhen Liang
- Jing Chen
View Affiliations

Affiliations: Department of Urology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China, Department of Urology Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: December 8, 2017 https://doi.org/10.3892/ol.2017.7561
Pages: 2252-2258
Copyright: © Shu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is an irreplaceable treatment for prostate cancer. However, the acquisition of chemoresistance is a common and critical problem that requires urgent solutions for the effective treatment of this disease. The aim of the present study was to determine whether the combination of quercetin with doxorubicin reversed the resistance of prostate cancer cells to doxorubicin‑based therapy. A prostate cancer (PC)3 cell line (PC3/R) with acquired doxorubicin‑resistance was established. A significant drug‑resistance to doxorubicin and high activation of the phosphoinositide 3‑kinase/protein kinase‑B (PI3K/AKT) pathway in PC3/R cells, compared with normal PC3 cells, was demonstrated. Notably, combination treatment of doxorubicin with quercetin significantly promoted the doxorubicin‑induced apoptosis in PC3/R cells through the mitochondrial/reaction oxygen species pathway. In PC3/R cells, a significant upregulation of tyrosine‑protein kinase‑met (c‑met) was observed compared with nromal PC3 cells. However, the response to quercetin treatment in PC3/R cells inhibited c‑met expression and the downstream PI3K/AKT pathway. In addition, induced expression of c‑met rescued quercetin‑promoted apoptosis in PC3/R cells treated with doxorubicin. The results of the present study indicated that quercetin is able to reverse prostate cancer cell doxorubicin resistance by downregulating the expression of c‑met. It may represent a potential strategy for reversing the chemoresistance of prostate cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Kopczyńska E: Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel. Contemp Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
3	Zhang W, Meng Y, Liu N, Wen XF and Yang T: Insights into chemoresistance of prostate cancer. Int J Biol Sci. 11:1160–1170. 2015. View Article : Google Scholar : PubMed/NCBI
4	Karnak D and Xu L: Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
5	He H, Tian W, Chen H and Deng Y: MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1. Mol Med Rep. 13:1923–1929. 2016. View Article : Google Scholar : PubMed/NCBI
6	Rivankar S: An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10:853–858. 2014. View Article : Google Scholar : PubMed/NCBI
7	De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G, Gardner K and De Siervi A: BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol Cancer Res. 9:1078–1090. 2011. View Article : Google Scholar : PubMed/NCBI
8	Carey JP, Knowell AE, Chinaranagari S and Chaudhary J: Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells. Anticancer Res. 33:4271–7278. 2013.PubMed/NCBI
9	Lv L, Qiu K, Yu X, Chen C, Qin F, Shi Y, Ou J, Zhang T, Zhu H, Wu J, et al: Amphiphilic Copolymeric micelles for doxorubicin and curcumin co-delivery to reverse multidrug resistance in breast cancer. J Biomed Nanotechnol. 12:973–985. 2016. View Article : Google Scholar : PubMed/NCBI
10	Pan C, Wang X, Shi K, Zheng Y, Li J, Chen Y, Jin L and Pan Z: MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism. PLoS One. 11:e01520902016. View Article : Google Scholar : PubMed/NCBI
11	Bischoff SC: Quercetin: Potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care. 11:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
12	Erlund I: Review of the flavonoids quercetin, hespertin and naringenin. dietary sources, bioactivities, bioavailability and epidemiology. Nutr Res. 24:851–874. 2004. View Article : Google Scholar
13	Ramos S: Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem. 18:427–442. 2007. View Article : Google Scholar : PubMed/NCBI
14	Li J, Tang C, Li L, Li R and Fan Y: Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo. J Exp Clin Cancer Res. 35:612016. View Article : Google Scholar : PubMed/NCBI
15	West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
16	Kang Q and Yan S: Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells. Exp Ther Med. 9:1345–1350. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zorov DB, Juhaszova M and Sollott SJ: Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 94:909–950. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jung KA, Choi BH and Kwak MK: The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 87:465–476. 2015. View Article : Google Scholar : PubMed/NCBI
19	Ferracini R, Longati P, Naldini L, Vigna E and Comoglio PM: Identification of the major autophosphorylation site of the Met⁄hepatocyte growth factor receptor tyrosine kinase. J Biol Chem. 266:19558–19564. 1991.PubMed/NCBI
20	Knudsen BS and Vande Woude G: Showering c-Met dependent cancers with drugs. Curr Opin Genet Dev. 18:87–96. 2008. View Article : Google Scholar : PubMed/NCBI
21	Han Y, Luo Y, Zhao J, Li M and Jiang Y: Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo. Oncol Lett. 8:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I and Fuse H: Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate. 69:346–351. 2009. View Article : Google Scholar : PubMed/NCBI
23	Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY and Chow KC: HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol. 38:559–565. 2008. View Article : Google Scholar : PubMed/NCBI
24	Que W and Chen J: Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep. 4:343–349. 2011.PubMed/NCBI
25	Toschi L and Jänne PA: Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor⁄MET signaling in cancer. Clin Cancer Res. 14:5941–5946. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hung TH, Li YH, Tseng CP, Lan YW, Hsu SC, Chen YH, Huang TT, Lai HC, Chen CM, Choo KB and Chong KY: Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Cancer Gene Ther. 22:262–270. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yao Y, Dou C, Lu Z, Zheng X and Liu Q: MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem. 35:983–996. 2015. View Article : Google Scholar : PubMed/NCBI
28	Trovato M, Torre ML, Ragonese M, Simone A, Scarfì R, Barresi V, Giuffrè G, Benvenga S, Angileri FF, Tuccari G, et al: HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. Endocrine. 44:735–743. 2013. View Article : Google Scholar : PubMed/NCBI
29	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
30	Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009. View Article : Google Scholar : PubMed/NCBI
31	Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.PubMed/NCBI
32	Li H, Zeng J and Shen K: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
33	Toren P and Zoubeidi A: Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (review). Int J Oncol. 45:1793–1801. 2014. View Article : Google Scholar : PubMed/NCBI
34	Tang KD and Ling MT: Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition. Curr Med Chem. 21:3048–3056. 2014. View Article : Google Scholar : PubMed/NCBI
35	Yang F, Song L, Wang H, Wang J, Xu Z and Xing N: Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (Review). Oncol Rep. 33:2659–2668. 2015. View Article : Google Scholar : PubMed/NCBI
36	Wang P, Henning SM, Magyar CE, Elshimali Y, Heber D and Vadgama JV: Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res. 35:732016. View Article : Google Scholar : PubMed/NCBI
37	Jung YH, Heo J, Lee YJ, Kwon TK and Kim YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
38	Yang F, Song L, Wang H, Wang J, Xu Z and Xing N: Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth. PLoS One. 10:e01282772015. View Article : Google Scholar : PubMed/NCBI
39	Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H and Chen QY: Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics. 3:160182016. View Article : Google Scholar : PubMed/NCBI